| Topic |
Issue # |
|
Abacavir + tenofovir + 3TC failure |
393 |
| Abbott raises Norvir price five fold |
397 |
| Access for all, Thailand conference theme |
395 |
| ADAP organizing |
388 |
| ADAP Washington trip |
397 |
| Aegis |
388 |
| Africa Action |
390 |
| Africa trials -- no drugs |
391 |
| African-Americans and AIDS Conference |
388, 397
|
|
AIDS Treatment News online publication |
397 |
| AIDS Treatment News |
396 |
| Antibiotic-resistant staph |
388 |
| Atazanavir (Reyataz) approved |
392 |
|
Bahamas antiretroviral prices, Clinton |
389 |
| Biomedical research cuts |
392 |
| Bush AIDS initiative |
388, 391
|
| Buyers' club lists |
397 |
|
Cholesterol management |
394 |
| Ciasullo, Eric, on returning to work |
395 |
| Clinical Care Options for Hepatitis |
391 |
| Clinical Care Options |
388 |
| Clinton Foundation lowers Caribbean price |
389 |
| Clinton Foundation, HAART 40 cents/day |
395 |
| Cohen, Dr. Cal, on Retroviruses conf., pt. 1 |
389 |
| Cohen, Dr. Cal, on Retroviruses conf., pt. 2 |
390 |
| Co-trimoxazole for staph |
388 |
| Counterfeit Procrit |
389 |
|
Deep salvage |
390 |
| Drug development |
397 |
|
Efavirenz vs. nevirapine |
389 |
| Emtriva (FTC) approved |
393 |
| Export problem, WTO |
394 |
|
Federal policy problems |
392 |
| Fosamprenavir approved |
395 |
| FTC (Emtriva) approved |
393 |
| Fundraising, online |
392 |
| FUZEON (T-20) |
389 |
|
Glaxo research grants |
391 |
| Global Fund to Fight AIDS, TB, and Malaria |
388 |
| Grassroots organizing |
388 |
|
Heart disease guidelines |
394 |
| Highly experienced patients |
390 |
| HIV Insite |
388 |
| HIV nutrition info for doctors |
391 |
| HIV treatment guidelines, July |
393 |
| HIV treatment guidelines, November 2003 |
396 |
| HIVandHepatitis.com |
388 |
| Hoffmann-La Roche, T-20 |
389 |
| Huge price variations in generics |
391 |
|
IAS conference reports on Web |
393 |
| International AIDS Society conf., Paris |
392 |
|
Lexiva (908, Fosamprenavir) |
389 |
| Lexiva approved |
395 |
|
Medicaid cuts planned |
390 |
| Medicaid organizing |
388 |
| Medscape |
388 |
| Microbicides |
391 |
| MRSA |
388 |
|
NATAP |
388 |
| Nelson Mandela on HIV treatment access |
393 |
| Neuropathy treatment, new guidelines |
396 |
| Nevirapine reduced maternal transmission |
394 |
| Nevirapine toxicity |
389 |
| Nevirapine vs. efavirenz |
389 |
| Norvir price fivefold rise |
397 |
|
Paris conference reports on Web |
393 |
| Pediatric HIV guidelines, November 2003 |
396 |
| Pharmaceutical company lobbying facts |
397 |
| Pharmacy benefits managers, profit |
391 |
| Philadelphia FIGHT |
391 |
| Planetwork conference |
392 |
| Pneumocystis still cause of death in U.S. |
391 |
| Prevention policy problems |
392 |
| Prices of drugs |
391 |
| Prison Health News |
390 |
| Prison skin infections |
388 |
|
Retroviruses conference, Web coverage |
388 |
| Returning to work after disability |
395 |
| Reyataz approved |
392 |
|
Safety net failure |
391 |
| SARS Web information |
390 |
| Save ADAP committee |
397 |
| Search for a Cure, clinical trials forum |
395 |
| Social network software, for fundraising |
392 |
| Social Security disability definition |
392 |
| Staph infection treatments |
388 |
| Starting antiretroviral therapy |
389 |
| Subscriptions to share |
396 |
|
T-20 cost |
389 |
| TAC (Treatment Action Campaign) |
390 |
| Tenofovir + ddI + 3TC failure |
395 |
| Thailand conference 2004, deadlines |
395 |
| The Body Web site |
388 |
| Treatment Action Campaign |
390 |
| Treatment interruption |
390, 394
|
| Triglycerides management |
394 |
| Trizivir arm stopped in trial |
390 |
|
UNAIDS report for 2003 |
396 |
|
VaxGen's AIDSVAX trial |
389 |
|
World AIDS: $4.7 billion -- WorldCom: $35 billion |
396 |
| World Trade Organization rules |
394 |
| WORLD, women and HIV |
391 |
| WTO rules limit access to poor countries |
394 |
This article was provided by AIDS Treatment News. It is a part of the publication AIDS Treatment News.
Email
Print-Friendly
Glossary
